Salud financiera de hoja de balance de Halozyme Therapeutics
Salud financiera controles de criterios 3/6
Halozyme Therapeutics tiene un patrimonio de accionistas total de $177.8M y una deuda total de $1.5B, lo que sitúa su ratio deuda-patrimonio en 844.1%. Sus activos y pasivos totales son $1.8B y $1.7B respectivamente. El BAIT de Halozyme Therapeutics es de $381.8M, por lo que su ratio de cobertura de intereses es de 43.7. Tiene efectivo e inversiones a corto plazo que ascienden a $463.5M.
Información clave
519.1%
Ratio deuda-patrimonio
US$1.50b
Deuda
| Ratio de cobertura de intereses | 46.2x |
| Efectivo | US$529.03m |
| Patrimonio | US$289.42m |
| Total pasivo | US$1.68b |
| Activos totales | US$1.97b |
Actualizaciones recientes sobre salud financiera
Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13
Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Recent updates
Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Jan 23Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Dec 09Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Oct 24Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($873.6M) de HALO superan a sus pasivos a corto plazo ($131.6M).
Pasivo a largo plazo: Los activos a corto plazo ($873.6M) de HALO no cubren sus pasivos a largo plazo ($1.5B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de HALO (583.5%) se considera alta.
Reducción de la deuda: El ratio deuda-patrimonio de HALO ha crecido de 40.5% a 844.1% en los últimos 5 años.
Cobertura de la deuda: La deuda de HALO está bien cubierta por el flujo de caja operativo (28.7%).
Cobertura de intereses: Los pagos de intereses de la deuda de HALO están bien cubiertos por el BAIT (43.7x cobertura).